RU2013147745A - Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей - Google Patents
Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей Download PDFInfo
- Publication number
- RU2013147745A RU2013147745A RU2013147745/15A RU2013147745A RU2013147745A RU 2013147745 A RU2013147745 A RU 2013147745A RU 2013147745/15 A RU2013147745/15 A RU 2013147745/15A RU 2013147745 A RU2013147745 A RU 2013147745A RU 2013147745 A RU2013147745 A RU 2013147745A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- hiv
- person
- bacterium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
1. Фармацевтическая композиция, включающая смесь крупнодисперсного антигена, который содержит один или несколько эпитопов из белков ВИЧ - Gag и/или Pol, и непатогенную бактерию.2. Фармацевтическая композиция по п.1, при этом указанный крупнодисперсный антиген выбран из вирусных частиц, вирусоподобных частиц, рекомбинантных вирусных частиц, конъюгата вирусных белков и конкатемера вирусных белков.3. Фармацевтическая композиция по п.2, при этом указанные рекомбинантные вирусные частицы или указанные вирусные частицы инактивированы.4. Фармацевтическая композиция по п.1, при этом указанная бактерия выбрана из ослабленных патогенных бактерий, инактивированных (необязательно, также ослабленных) патогенных бактерий и непатогенных молочнокислых бактерий.5. Фармацевтическая композиция по п.4, при этом указанная бактерия является бактерией рода Lactobacillus.6. Фармацевтическая композиция по п.1, которая является фармацевтической композицией для введения через слизистые, или внутрикожно, или интраэпителиально.7. Фармацевтическая композиция по п.6, которая является фармацевтической композицией для перорального приема.8. Фармацевтическая композиция по п.1 для применения в способе профилактики и/или лечения заболевания ВИЧ у человека, которому это необходимо.9. Фармацевтическая композиция по п.1 для применения в способе защиты человека от ВИЧ.10. Фармацевтическая композиция по п.1 для применения в способе защиты человека от сероконверсии, вызванной ВИЧ.11. Фармацевтическая композиция по п.1, которая индуцирует и, предпочтительно, поддерживает антиген-специфическую иммунную защиту против ВИЧ у человека.12. Фармацевтическая композици
Claims (15)
1. Фармацевтическая композиция, включающая смесь крупнодисперсного антигена, который содержит один или несколько эпитопов из белков ВИЧ - Gag и/или Pol, и непатогенную бактерию.
2. Фармацевтическая композиция по п.1, при этом указанный крупнодисперсный антиген выбран из вирусных частиц, вирусоподобных частиц, рекомбинантных вирусных частиц, конъюгата вирусных белков и конкатемера вирусных белков.
3. Фармацевтическая композиция по п.2, при этом указанные рекомбинантные вирусные частицы или указанные вирусные частицы инактивированы.
4. Фармацевтическая композиция по п.1, при этом указанная бактерия выбрана из ослабленных патогенных бактерий, инактивированных (необязательно, также ослабленных) патогенных бактерий и непатогенных молочнокислых бактерий.
5. Фармацевтическая композиция по п.4, при этом указанная бактерия является бактерией рода Lactobacillus.
6. Фармацевтическая композиция по п.1, которая является фармацевтической композицией для введения через слизистые, или внутрикожно, или интраэпителиально.
7. Фармацевтическая композиция по п.6, которая является фармацевтической композицией для перорального приема.
8. Фармацевтическая композиция по п.1 для применения в способе профилактики и/или лечения заболевания ВИЧ у человека, которому это необходимо.
9. Фармацевтическая композиция по п.1 для применения в способе защиты человека от ВИЧ.
10. Фармацевтическая композиция по п.1 для применения в способе защиты человека от сероконверсии, вызванной ВИЧ.
11. Фармацевтическая композиция по п.1, которая индуцирует и, предпочтительно, поддерживает антиген-специфическую иммунную защиту против ВИЧ у человека.
12. Фармацевтическая композиция по п.11, при этом указанная иммунная защита характеризуется снижением и, предпочтительно, супрессией вирусной нагрузки ВИЧ у указанного человека.
13. Фармацевтическая композиция по любому из пп.11 или 12, при этом указанная иммунная защита характеризуется присутствием регуляторных CD8+ Т-клеток, супрессирующих активацию CD4+ Т-клеток, презентирующих антигены белков ВИЧ - Gag и/или Pol - у указанного человека.
14. Фармацевтическая композиция по п.13, при этом указанная иммунная защита определяется у указанного человека путем детекции in vitro присутствия или активности регуляторных CD8+ Т-клеток указанного человека, и при этом указанные регуляторные CD8+ Т-клетки являются ограниченными MHC-Ib/E регуляторными CD8+ Т-клетками.
15. Фармацевтической набор для профилактики и/или лечения заболевания ВИЧ у человека, которому это необходимо, содержащий:
- в первом контейнере - крупнодисперсный антиген, содержащий один или несколько эпитопов из белков ВИЧ - Gag и/или Pol; и
- во втором контейнере - непатогенную живую бактерию,
при этом указанный антиген и указанная бактерия находятся в фармацевтически приемлемых носителях, пригодных для ведения через слизистую, или внутрикожно, или интраэпителиально.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2011/072481 | 2011-04-06 | ||
CNPCT/CN2011/072481 | 2011-04-06 | ||
US201161534088P | 2011-09-13 | 2011-09-13 | |
US61/534,088 | 2011-09-13 | ||
CNPCT/CN2012/070761 | 2012-01-30 | ||
CNPCT/CN2012/070761 | 2012-01-30 | ||
US201261609051P | 2012-03-09 | 2012-03-09 | |
US61/609,051 | 2012-03-09 | ||
PCT/IB2012/000857 WO2012137071A2 (en) | 2011-04-06 | 2012-04-06 | Pharmaceutical compositions for preventing and/or treating an hiv disease in humans |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2013147745A true RU2013147745A (ru) | 2015-05-20 |
RU2609769C2 RU2609769C2 (ru) | 2017-02-02 |
Family
ID=46969619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013147745A RU2609769C2 (ru) | 2011-04-06 | 2012-04-06 | Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей |
Country Status (19)
Country | Link |
---|---|
US (1) | US9839684B2 (ru) |
EP (3) | EP2694101B1 (ru) |
JP (1) | JP6054370B2 (ru) |
KR (1) | KR101814857B1 (ru) |
CN (1) | CN105709221B (ru) |
AP (1) | AP2013007166A0 (ru) |
AU (1) | AU2012238351B2 (ru) |
BR (1) | BR112013025481B8 (ru) |
CA (1) | CA2832022C (ru) |
CL (1) | CL2013002836A1 (ru) |
DK (1) | DK2694101T3 (ru) |
ES (1) | ES2606511T3 (ru) |
IL (1) | IL228666A (ru) |
MX (1) | MX343037B (ru) |
PL (1) | PL2694101T3 (ru) |
PT (1) | PT2694101T (ru) |
RU (1) | RU2609769C2 (ru) |
SG (1) | SG194079A1 (ru) |
WO (1) | WO2012137071A2 (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL159048A0 (en) * | 2001-06-21 | 2004-05-12 | Genentech Inc | Sustained release formulation |
JO3753B1 (ar) | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
JP6464201B2 (ja) * | 2015-01-30 | 2019-02-06 | 国立大学法人 東京大学 | 乳酸菌含有組成物、hpv感染症及びhpv関連腫瘍の少なくともいずれかの治療用経口医薬組成物、及び粘膜免疫誘導剤 |
US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
AU2020243095A1 (en) * | 2019-03-21 | 2021-10-21 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
KR102507852B1 (ko) * | 2020-01-10 | 2023-03-09 | 이뮤노바이옴 주식회사 | 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도 |
EP4288091A1 (en) * | 2021-02-02 | 2023-12-13 | Provaxus, Inc. | Novel immunomodulation platform and methods of use |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0243029A1 (en) | 1986-04-08 | 1987-10-28 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Recombinant vaccinia virus expressing human retrovirus gene |
JPS6485072A (en) | 1987-09-25 | 1989-03-30 | Nat Inst Health | Recombinant vaccinia virus |
JPH01148183A (ja) | 1987-12-04 | 1989-06-09 | Hiroshi Shibuta | 組み換えワクチニアウイルス |
JP3140757B2 (ja) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
US5861282A (en) | 1989-10-16 | 1999-01-19 | Whitehead Institute For Biomedical Research | Non-infectious HIV particles and uses therefor |
HUT60506A (en) | 1989-11-20 | 1992-09-28 | Oncogen | Process for producing non-replicable, recombinant retrovirus particles and antiviral and immunogenic preparations |
ES2140380T5 (es) | 1990-03-21 | 2005-03-16 | Geneart Gmbh | Secuencias de adn que codifican polipeptidos gag retroviricos modificados y vacunas que las contienen o agregados de las mismas. |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
EP1156102A1 (en) | 1991-06-14 | 2001-11-21 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
DE69133333T2 (de) | 1991-08-26 | 2004-07-29 | Baxter Healthcare S.A. | Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken |
DE4141741A1 (de) | 1991-12-13 | 1993-06-17 | Gisela Kielmann | Verfahren zur bekaempfung des human imune deficiency virus |
US6511845B1 (en) | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
US6136318A (en) | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
WO1995007099A1 (fr) | 1993-09-09 | 1995-03-16 | The Nisshin Oil Mills, Ltd. | Vaccin et procede pour sa production |
JPH07170982A (ja) | 1993-09-09 | 1995-07-11 | Nisshin Oil Mills Ltd:The | ワクチンおよびその製造方法 |
US6080408A (en) | 1994-08-22 | 2000-06-27 | Connaught Laboratories Limited | Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles |
AU3958895A (en) | 1994-10-18 | 1996-05-06 | Board Of Regents, The University Of Texas System | Membrane expression of heterologous genes |
AU729518B2 (en) | 1995-06-07 | 2001-02-01 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
US5741492A (en) | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
JPH1085072A (ja) | 1996-09-13 | 1998-04-07 | Kichinosuke Takemaru | 家具転倒防止器具 |
US6001155A (en) | 1997-03-17 | 1999-12-14 | Pease; John R. | Polyphasic pressurized homogenizer |
HRP980143A2 (en) * | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
US5895758A (en) * | 1997-06-10 | 1999-04-20 | Bio-Energy Systems | Strain of lactobacillus Plantarum |
WO1998056931A1 (en) | 1997-06-11 | 1998-12-17 | Institut Pasteur | Attenuated recombinant mycobacteria useful as immunogens or as vaccine components |
JP3899165B2 (ja) | 1997-08-06 | 2007-03-28 | ビー・エル・オートテック株式会社 | ロボットアームの過負荷保護装置 |
US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
US6121021A (en) | 1997-12-16 | 2000-09-19 | Connaught Laboratories Limited | Constitutive expression of non-infectious HIV-like particles |
US7189402B1 (en) | 1998-02-06 | 2007-03-13 | Research Development Foundation | Live vaccine for human immunodeficiency virus |
US6828460B2 (en) | 1999-03-22 | 2004-12-07 | Pfizer Inc. | Resorcinol derivatives |
US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
CA2378539A1 (en) | 1999-07-06 | 2001-01-11 | Merck & Co., Inc. | Adenovirus carrying gag gene hiv vaccine |
EP1084709A1 (en) | 1999-09-17 | 2001-03-21 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Oral recombinant lactobacilli vaccines |
JP2003512077A (ja) | 1999-10-26 | 2003-04-02 | インターナショナル エイズ バクシーン イニシアティブ | アルファウイルスレプリコンを発現する侵襲性細菌 |
US20040105871A1 (en) | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
US6544780B1 (en) | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
US20020155127A1 (en) | 2000-06-02 | 2002-10-24 | Danher Wang | Genetic vaccine against human immunodeficiency virus |
WO2002022080A2 (en) | 2000-09-15 | 2002-03-21 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
US6733993B2 (en) | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
US20040101957A1 (en) | 2001-09-14 | 2004-05-27 | Emini Emilio A. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
WO2002031168A2 (en) | 2000-10-10 | 2002-04-18 | Genstar Therapeutics | Minimal adenoviral vector and recombinant vaccines based thereon |
GB0030857D0 (en) | 2000-12-18 | 2001-01-31 | Medical Res Council | Therapeutic compositions |
KR20020059856A (ko) | 2001-01-08 | 2002-07-16 | 김철중 | 에이치아이브이 유사입자의 제조 |
AU2002252199B2 (en) | 2001-03-08 | 2008-01-03 | Emory University | MVA expressing modified HIV envelope, GAG, and POL genes |
WO2002102409A1 (en) | 2001-06-19 | 2002-12-27 | Medical Research Council | Inactivated mycobacterial ompatb and uses thereof |
AU2002332736A1 (en) | 2001-08-30 | 2003-03-18 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | New adenovirus type 7 vectors |
US20070077257A1 (en) | 2001-09-14 | 2007-04-05 | Emini Emilio A | Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications |
CA2467271A1 (en) | 2001-11-14 | 2003-06-26 | Novavax, Inc. | Mycobacterial vaccine |
WO2003050238A2 (en) | 2001-12-11 | 2003-06-19 | University Of Iowa Research Foundation | Receptor-targeted adenoviral vectors |
US20040009937A1 (en) | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
WO2003063786A2 (en) | 2002-01-31 | 2003-08-07 | Symbigene, Inc. | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
DE60326444D1 (de) | 2002-04-26 | 2009-04-16 | Inst Clayton De La Rech | Verbesserte chimäre glykoproteine und pseudotypisierte lentivirale vektoren |
JP2003321391A (ja) | 2002-04-30 | 2003-11-11 | Japan Science & Technology Corp | 組換えワクシニアウイルスを用いたhivワクチン |
DE10221411B4 (de) | 2002-05-14 | 2004-07-08 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Rekombinantes Fowlpox-Virus |
US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
CA2487895A1 (en) * | 2002-05-31 | 2003-12-11 | Ciphergen Biosystems, Inc. | Defensins: use as antiviral agents |
CN1490056A (zh) | 2002-10-18 | 2004-04-21 | ��¡���ɵ°��̲��о����� | 针对hiv-1的免疫方法和组合物 |
WO2004087201A2 (en) | 2003-03-28 | 2004-10-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mva virus expressing modified hiv envelope, gag, and pol genes |
JP2007518460A (ja) | 2003-05-09 | 2007-07-12 | イントラヴァック インコーポレーテッド | 皮内、皮下及び筋肉内注射用の無針注射器及びアンプル |
WO2005017208A1 (en) | 2003-07-31 | 2005-02-24 | George Mason Intellectual Properties, Inc. | Compositions and methods for treating or preventing hiv infection |
AU2004269379A1 (en) * | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Immunogenic HIV compositions and related methods |
JP2007037402A (ja) | 2003-11-28 | 2007-02-15 | Primmune:Kk | 抗ヒト免疫不全ウイルス感染防御用キメラ5型/35型アデノウイルスベクター |
WO2005111205A1 (en) | 2004-05-18 | 2005-11-24 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Tuberculosis vaccine |
US8541167B2 (en) * | 2004-06-03 | 2013-09-24 | Saint Louis University | Methods and compositions for vaccination |
WO2006012320A1 (en) | 2004-06-25 | 2006-02-02 | Dow Agrosciences Llc | Process for the preparation of 4-trifluoromethyl-2(1h)-pyridinone |
WO2006026667A2 (en) | 2004-08-27 | 2006-03-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes |
CN101056977B (zh) * | 2004-10-04 | 2013-01-30 | 拜欧瓦克西姆有限公司 | 用于治疗hiv感染患者的亚型匹配的灭活全病毒疫苗 |
EP1856143A2 (en) | 2005-02-24 | 2007-11-21 | Medical Research Council | Hivcon: anhiv immunogen and uses thereof |
AU2006245920A1 (en) | 2005-05-12 | 2006-11-16 | Glaxo Group Limited | Vaccine composition |
EP1723965A1 (en) | 2005-05-18 | 2006-11-22 | Stallergenes Sa | Compositions for antigen-specific induction of immuno-tolerance via oral immunization |
WO2007140613A1 (en) | 2006-06-06 | 2007-12-13 | Mcgill University | Fermented milk product and use thereof |
JP5713672B2 (ja) | 2007-04-12 | 2015-05-07 | ジェニファー ライター, | 結核のワクチンおよびその使用方法 |
WO2009093900A1 (en) | 2008-01-25 | 2009-07-30 | Stichting Top Institute Food And Nutrition | Mid-log phase lactic acid bacteria for inducing immune tolerance in a subject |
-
2012
- 2012-04-06 AP AP2013007166A patent/AP2013007166A0/xx unknown
- 2012-04-06 PT PT127219210T patent/PT2694101T/pt unknown
- 2012-04-06 JP JP2014503228A patent/JP6054370B2/ja active Active
- 2012-04-06 SG SG2013074190A patent/SG194079A1/en unknown
- 2012-04-06 EP EP12721921.0A patent/EP2694101B1/en active Active
- 2012-04-06 CA CA2832022A patent/CA2832022C/en active Active
- 2012-04-06 EP EP15189227.0A patent/EP3000476A1/en not_active Withdrawn
- 2012-04-06 AU AU2012238351A patent/AU2012238351B2/en not_active Ceased
- 2012-04-06 WO PCT/IB2012/000857 patent/WO2012137071A2/en active Application Filing
- 2012-04-06 RU RU2013147745A patent/RU2609769C2/ru active
- 2012-04-06 US US14/009,250 patent/US9839684B2/en active Active
- 2012-04-06 KR KR1020137029030A patent/KR101814857B1/ko active IP Right Grant
- 2012-04-06 PL PL12721921T patent/PL2694101T3/pl unknown
- 2012-04-06 DK DK12721921.0T patent/DK2694101T3/en active
- 2012-04-06 MX MX2013011540A patent/MX343037B/es active IP Right Grant
- 2012-04-06 ES ES12721921.0T patent/ES2606511T3/es active Active
- 2012-04-06 EP EP16191838.8A patent/EP3173096A1/en not_active Withdrawn
- 2012-04-06 BR BR112013025481A patent/BR112013025481B8/pt not_active IP Right Cessation
- 2012-04-06 CN CN201510856888.3A patent/CN105709221B/zh not_active Expired - Fee Related
-
2013
- 2013-10-01 IL IL228666A patent/IL228666A/en active IP Right Grant
- 2013-10-02 CL CL2013002836A patent/CL2013002836A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gong et al. | The current status, challenges, and future developments of new tuberculosis vaccines | |
RU2013147745A (ru) | Фармацевтическая композиция для профилактики и(или) лечения заболеваний вич у людей | |
Rosendahl Huber et al. | T cell responses to viral infections–opportunities for peptide vaccination | |
Mastelic et al. | Mode of action of adjuvants: implications for vaccine safety and design | |
Riedl et al. | The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice | |
JP2014511856A5 (ru) | ||
Belyakov et al. | Mucosal immunity and HIV-1 infection: applications for mucosal AIDS vaccine development | |
Volpatti et al. | Polymersomes decorated with the SARS-CoV-2 spike protein receptor-binding domain elicit robust humoral and cellular immunity | |
Borsutzky et al. | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant | |
JP2017523166A (ja) | ヒト免疫不全ウイルスi(hiv)の病理学的影響を減少及び/若しくは遅延させるか又は後天性免疫不全症候群(aids)を発症するリスクを低減させる方法 | |
Heng et al. | Impact of sex steroid ablation on viral, tumour and vaccine responses in aged mice | |
Ayash-Rashkovsky et al. | Generation of Th1 immune responses to inactivated, gp120-depleted HIV-1 in mice with a dominant Th2 biased immune profile via imunostimulatory oligonucleotides—relevance to AIDS vaccines in developing countries | |
Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
Farnós et al. | The recombinant rabbit hemorrhagic disease virus VP60 protein obtained from Pichia pastoris induces a strong humoral and cell-mediated immune response following intranasal immunization in mice | |
Sisteré-Oró et al. | Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate | |
Li et al. | The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis | |
AU2011269729A1 (en) | Constrained immunogenic compositions and uses therefor | |
WO2012137072A1 (en) | Therapeutic vaccine compositions inducing tolerance to hiv for treating hiv infections in humans | |
Medaglini et al. | The European effort towards the development of mucosal vaccines for poverty-related diseases | |
Kim et al. | 1955. A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin vs. Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants≤ 3 Months of Age | |
Johndrow | Route Specific Effects of Lipoprotein Agonists of TLR2 on CD4 T Cell Priming | |
Yoshita Bhide et al. | pter 2 | |
Javadi et al. | Synthesis and characterization of physicochemical and immunological properties of recombinant NS3-G2 dendrimer conjugate | |
Iglesias | Conference report:“30 years of HIV science. Imagine the future” | |
Knudsen | Alphavirus replicon-based strategies for vaccination |